A Study of RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression)

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 19, 2022

Primary Completion Date

December 30, 2024

Study Completion Date

December 30, 2025

Conditions

Melanoma, Stage IIHER2-positiveAdvanced Melanoma

Interventions

DRUG

RC48-ADC

2.0 mg/kg IV every 2 weeks

Trial Locations (4)

RECRUITING

Fujian cancer hospital, Fuzhou

RECRUITING

The First Hospital of Jilin University, Changchun

RECRUITING

Zhejiang cancer hospital, Hangzhou

RECRUITING

Beijing Cancer Hospital, Beijing

All Listed Sponsors

lead

RemeGen Co., Ltd.

INDUSTRY